Monthly Archive: March 2015

Mar 31

The US Food and Drug Administration has approved the Impella 2.5 System, a miniature blood pump system designed to help certain patients maintain stable heart function and circulation during certain high-risk percutaneous coronary intervention (HRPCI)

The US Food and Drug Administration has approved the Impella 2.5 System, a miniature blood pump system designed to help certain patients maintain stable heart function and circulation during certain high-risk percutaneous coronary intervention (HRPCI) procedures, such as balloon angioplasty and stenting, which re-open coronary arteries that are narrowed or blocked due to severe coronary …

Continue reading »

Mar 31

Adding two non-invasive imaging tests to traditional cardiovascular disease risk factor assessment more precisely predicts a healthy patient’s future risk of heart attack

Adding two non-invasive imaging tests to traditional cardiovascular disease risk factor assessment more precisely predicts a healthy patient’s future risk of heart attack, stroke, or premature death, suggests a study published in the Journal of the American College of Cardiology (JACC).

Mar 30

In patients with coronary artery disease undergoing coronary angiography, measuring high-sensitivity C-reactive protein (hs-CRP) and lipoprotein(a) (Lp(a))

In patients with coronary artery disease undergoing coronary angiography, measuring high-sensitivity C-reactive protein (hs-CRP) and lipoprotein(a) (Lp(a)) may help stratify patients into different categories of risk, with investigators reporting that those with higher levels of both biomarkers seem to be at a significantly increased risk of major adverse cardiovascular events (MACE), suggests a new study …

Continue reading »

Mar 30

Establishing age- and sex-specific 10-year risk thresholds to identify adults to be considered for statins might improve the treatment’s number-needed-to-treat balance and enhance the overall performance of the treatment guidelines

Establishing age- and sex-specific 10-year risk thresholds to identify adults to be considered for statins might improve the treatment’s number-needed-to-treat balance and enhance the overall performance of the treatment guidelines, suggests new research presented at the American College of Cardiology (ACC) 2015 Scientific Sessions.

Mar 29

Background statin therapy, even the use of high-dose statin therapy

Background statin therapy, even the use of high-dose statin therapy, does not seem to affect the ability of alirocumab to reduce LDL-cholesterol levels in patients at high cardiovascular risk, suggests a new analysis of the investigational inhibitor of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor. The study was presented at EAS 2015: the European Atherosclerosis …

Continue reading »

Mar 29

Moderately strenuous aerobic exercise can improve cardiovascular health in patients who have received an implantable cardioverter-defibrillator (ICD)

Moderately strenuous aerobic exercise can improve cardiovascular health in patients who have received an implantable cardioverter-defibrillator (ICD), without causing the device shocks that many patients fear working out might cause, suggests new research published in Circulation.

Mar 28

Although rarely selected, ulnar–artery catheterization is comparable, with respect to clinical outcomes, to the more common radial access during PCI

Although rarely selected, ulnar–artery catheterization is comparable, with respect to clinical outcomes, to the more common radial access during PCI, report investigators from the Ajmer Ulnar Artery Working Group Study (AJULAR). The data were presented at the American College of Cardiology (ACC) 2015 Scientific Sessions.

Mar 28

The investigational oral potassium–binding agent patiromer appeared safe and effective in a 1–year, phase 2 study of patients with chronic kidney disease (CKD)

The investigational oral potassium–binding agent patiromer appeared safe and effective in a 1–year, phase 2 study of patients with chronic kidney disease (CKD), type 2 diabetes, and hypertension, with or without heart failure (HF), and with mild or moderate hyperkalemia due to treatment with renin–angiotensinaldosterone system (RAAS) inhibitors. The findings were presented at the American …

Continue reading »

Mar 27

In the first larger–scale randomized controlled trial to assess long–term efficacy and safety of a selective serotonin reuptake inhibitor (SSRI) in patients with chronic heart failure (CHF)

In the first larger–scale randomized controlled trial to assess long–term efficacy and safety of a selective serotonin reuptake inhibitor (SSRI) in patients with chronic heart failure (CHF) presented at the American College of Cardiology (ACC) 2015 Scientific Sessions, there were no significant differences in clinical outcomes between escitalopram and placebo. The Mortality, Morbidity and Mood …

Continue reading »

Mar 27

A European panel of experts has released a new consensus statement to advise physicians on how to deal with patients who develop muscle symptoms while taking statins

A European panel of experts has released a new consensus statement to advise physicians on how to deal with patients who develop muscle symptoms while taking statins, but they stress statins must continue to be tried in these difficult-to-manage patients. The statement was published in the European Heart Journal.

Older posts «